Want to Join Our Team?
Learn about Blue Matter's innovative work experiences, enriching development opportunities, team-oriented "People First" culture, and a lot more.
Insights
Access our ever-expanding library of thought leadership resources for strategic leaders and professionals in biopharma. It’s full of useful content addressing industry challenges, best practices, therapeutic markets, innovative ideas, and forward-looking insights.
Featured Whitepaper
AI Is Everywhere in Biopharma R&D…Except in the Productivity Numbers: The AI Paradox and How to Overcome It
Learn More >
Featured Whitepaper
5 Key Dynamics Reshaping the Market for Physician-Administered Drugs
Learn More >
Whitepaper
Boston Biopharma Discussion Synthesis (May 13, 2026)
Whitepaper
Key Success Factors for Building a Best Practice Key Account Management Organization
Whitepaper
Key Success Factors for Building a Best Practice Patient Services Organization
Whitepaper
Key Success Factors to Building a Best Practice US Market Access Organization
Whitepaper
5 Key Dynamics Reshaping the Market for Physician-Administered Drugs
Blog
5 Key Dynamics Reshaping the Market for Physician-Administered Drugs
Blog
Disruption & Uncertainty: The US Market Access Environment & What It Means for Biopharma in 2026
Blog
Guidance for Evaluating MFN: Part 3 – Key Considerations for Deals
Blog
Guidance for Evaluating MFN: Part 2 – Impact on Pharma Channel Partner and Customer Business
Blog
Guidance for Evaluating MFN: Part 1 – Key Questions for Biopharma Manufacturers
Whitepaper
The Joint Clinical Assessment: Expectations and Strategic Implications
Blog
Surveying the Shifting Landscape in European Market Access (Part 3: The JCA – Expectations and Strategic Implications)
Blog
Surveying the Shifting Landscape in European Market Access (Part 2: Changes for Orphan Drugs)
Blog
Surveying the Shifting Landscape in European Market Access (Part 1)
Blog
August 2023 Roundup of HTA Decisions in Three Top European Markets and a Perspective on How to Sustain a High ASMR Score at Reassessment by HAS
Blog
July 2023 Roundup of HTA Decisions in Oncology and a Perspective on the UK Cancer Drugs Fund (CDF)
